유럽의 급성기 신드로믹 검사 시장 - 분석 및 예측(2023-2033년)

Europe Acute Care Syndromic Testing Market - Analysis and Forecast, 2023-2033

US $ 1,475 ￦ 2,134,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 2,225 ￦ 3,219,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유럽의 급성기 신드로믹 검사 시장 규모는 2022년 9억 달러로 평가되며 2023년부터 2033년까지 CAGR 8.95%로 확대되어 2033년에는 23억 2,000만 달러에 달할 것으로 예상됩니다.

신드로믹 패널과 같은 분자 진단 기술은 여러 병원균을 동시에 검출할 수 있습니다. 이러한 병원체는 일반적으로 동등하거나 중복되는 임상 증상을 나타내므로 환자 관리가 용이하고 특정 증상의 진단이 더 쉬워집니다.

주요 시장 통계
예측 기간	2023-2033년
2023년 평가액	9억 8,000만 달러
2033년 전망	23억 2,000만 달러
CAGR	8.95%

감염병 조기 발견에 대한 수요가 증가함에 따라 유럽의 급성기 신드로믹 검사 산업은 눈에 띄게 빠르게 성장하고 있습니다. 전염병의 발생과 전염병의 유행이 이러한 증가에 크게 기여하고 있습니다. 또한 전 세계 기온이 상승하고 다양한 지역에서 새로운 전염병이 발견되는 것도 이 산업의 성장을 촉진하고 있습니다.

유럽의 급성기 신드로믹 검사 분야는 유망한 헬스케어 솔루션이 제공되고 있으며, 향후 더 많은 발전을 기대할 수 있습니다. 급성기 신드로믹 검사 시장은 감염의 조기 발견, 치료 계획, 진단 및 모니터링을 위한 장비의 발전으로 인해 성장하고 있습니다. 유럽 시장에서는 의료 인프라에 대한 투자와 첨단 진단 기술의 도입이 증가하고 있으며, 이는 급성기 신드로믹 패널 검사 시장의 성장을 더욱 촉진하고 있습니다. 또한, 일상적인 임상에서 신드로믹 패널 검사의 통합을 촉진하는 유리한 규제와 이니셔티브도 있습니다.

이 보고서는 유럽의 급성기 신드로믹 검사 시장에 대해 조사했으며, 시장 개요와 함께 최종사용자별, 국가별 동향, 시장 진입 기업 개요 등을 제공합니다.

목차

제1장 시장

• 제품 정의
• 포함 기준과 제외 기준
• 시장 범위
• 조사 방법

제2장 시장 개요

• 개요
• 급성기 신드로믹 검사 워크플로우 분석
• 시장 발자국과 성장 가능성
• 잠재성

제3장 업계 인사이트

• 이해관계자의 관점(N=20)
  • 의사의 인식
  • 지불자의 인식
  • 투자가의 인식
• 급성기 신드로믹 검사 시장의 법적 및 규제 체계
  • 북미의 규제 체계
  • 유럽의 규제 체계
  • 아시아태평양의 규제 체계
  • 라틴아메리카의 규제 체계
  • 기타 지역의 규제 체계
• 제품 벤치마크

제4장 시장 역학

• 개요
• 영향 분석
• 시장 성장 촉진요인
• 시장 과제
• 시장 기회

제5장 유럽

• 개요
• 유럽
  • 유럽의 급성기 신드로믹 검사 시장, 최종사용자별
  • 유럽의 급성기 신드로믹 검사 시장, 국가별

제6장 기업 개요

• 급성기 신드로믹 검사 시장 진출 기업
• Biocartis NV
• bioMerieux SA(BioFire Diagnostics)
• DiaSorin S.p.A(Luminex Corporation)
• Eurofins Scientific(Eurofins Viracor)
• QIAGEN N.V.
• QuantuMDx Group Ltd.
• Siemens Healthineers AG

ksm

영문 목차

영문목차

“The Europe Acute Care Syndromic Testing Market Expected to Reach $2.32 Billion by 2033.”

Introduction to Europe Acute Care Syndromic Testing Market

The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033. Molecular diagnostics techniques such as syndromic panels are capable of simultaneously detecting several pathogens. These pathogens typically exhibit comparable or overlapping clinical symptomatology, making patient management easier and specific symptom diagnosis more straightforward.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$0.98 Billion
2033 Forecast	$2.32 Billion
CAGR	8.95%

Market Introduction

The increasing demand for early infectious illness identification has led to a notable surge in the acute care syndromic testing industry in Europe. The incidence of pandemics and the prevalence of infectious diseases have been major contributors to this rise. Furthermore, the expansion of the industry has been aided by the rise in global temperatures and the discovery of new infectious diseases in different places.

Promising healthcare solutions are available in the European acute care syndromic testing sector, and more developments may be possible. The acute care syndromic testing market is growing as a result of the advancement of instruments for early detection, treatment planning, diagnosis, and monitoring of infectious diseases. The Europe market is witnessing increasing investments in healthcare infrastructure and the adoption of advanced diagnostic technologies, further boosting the growth of the acute care syndromic panel testing market. Additionally, favorable regulations and initiatives promoting the integration of syndromic panel testing in routine clinical.

Market Segmentation

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe acute care syndromic testing market has been extensively segmented on the basis of various categories, such as end user and Country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
• 1.3 Market Scope
  • 1.3.1 Key Questions Answered in the Report
• 1.4 Research Methodology
  • 1.4.1 Acute Care Syndromic Testing Market: Research Methodology
  • 1.4.2 Data Sources
    • 1.4.2.1 Primary Data Sources
    • 1.4.2.2 Secondary Data Sources
  • 1.4.3 Market Estimation Model
  • 1.4.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Overview
• 2.2 Acute Care Syndromic Testing Workflow Analysis
• 2.3 Market Footprint and Growth Potential
• 2.4 Future Potential

3 Industry Insight

• 3.1 Stakeholder's Perspective (N=20)
  • 3.1.1 Physician's Perception
  • 3.1.2 Payor's Perception
  • 3.1.3 Investor's Perception
• 3.2 Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1 Regulatory Framework in North America
    • 3.2.1.1 The U.S.
    • 3.2.1.2 Canada
  • 3.2.2 Regulatory Framework in Europe
  • 3.2.3 Regulatory Framework in Asia-Pacific
    • 3.2.3.1 Japan
    • 3.2.3.2 China
    • 3.2.3.3 India
    • 3.2.3.4 South Korea
    • 3.2.3.5 Australia
  • 3.2.4 Regulatory Framework in Latin America
    • 3.2.4.1 Brazil
    • 3.2.4.2 Mexico
  • 3.2.5 Regulatory Framework in Rest-of-the-World
    • 3.2.5.1 U.A.E.
    • 3.2.5.2 K.S.A.
• 3.3 Product Benchmarking

4 Market Dynamics

• 4.1 Overview
• 4.2 Impact Analysis
• 4.3 Market Drivers
  • 4.3.1 Faster Results Acquired with Syndromic Tests
  • 4.3.2 Increasing Incidence of Infectious Diseases
  • 4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4 Reduced Severe Adverse Effects from Pathogens
• 4.4 Market Challenges
  • 4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2 Lack of High-Complexity Testing Centres
• 4.5 Market Opportunities
  • 4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Europe

• 5.1 Overview
• 5.2 Europe
  • 5.2.1 Europe Acute Care Syndromic Testing Market, By End User
  • 5.2.2 Europe Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1 Germany
    • 5.2.2.2 France
    • 5.2.2.3 U.K.
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest-of-Europe

6 Company Profiles

• 6.1 Overview
• 6.2 Acute Care Syndromic Testing Ecosystem Active Players
• 6.3 Biocartis NV
  • 6.3.1 Company Overview
  • 6.3.2 Role of Biocartis NV in the Acute Care Syndromic Testing Market
  • 6.3.3 Financials
  • 6.3.4 Recent Developments
    • 6.3.4.1 Business Strategies
  • 6.3.5 Analyst Perspective
• 6.4 bioMerieux SA (BioFire Diagnostics)
  • 6.4.1 Company Overview
  • 6.4.2 Role of bioMerieux SA (BioFire Diagnostics) in the Acute Care Syndromic Testing Market
  • 6.4.3 Financials
  • 6.4.4 Recent Developments
    • 6.4.4.1 Business Strategies
  • 6.4.5 Analyst Perspective
• 6.5 DiaSorin S.p.A (Luminex Corporation)
  • 6.5.1 Company Overview
  • 6.5.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Acute Care Syndromic Testing Market
  • 6.5.3 Financials
  • 6.5.4 Recent Developments
    • 6.5.4.1 Corporate Strategies
    • 6.5.4.2 Business Strategies
  • 6.5.5 Analyst Perspective
• 6.6 Eurofins Scientific (Eurofins Viracor)
  • 6.6.1 Company Overview
  • 6.6.2 Role of Eurofins Scientific (Eurofins Viracor) in the Acute Care Syndromic Testing Market
  • 6.6.3 Financials
  • 6.6.4 Recent Developments
    • 6.6.4.1 Business Strategies
  • 6.6.5 Analyst Perspective
• 6.7 QIAGEN N.V.
  • 6.7.1 Company Overview
  • 6.7.2 Role of QIAGEN N.V. in the Acute Care Syndromic Testing Market
  • 6.7.3 Financials
  • 6.7.4 Recent Developments
    • 6.7.4.1 Business Strategies
  • 6.7.5 Analyst Perspective
• 6.8 QuantuMDx Group Ltd.
  • 6.8.1 Company Overview
  • 6.8.2 Role of QuantuMDx Group Ltd. in the Acute Care Syndromic Testing Market
  • 6.8.3 Recent Developments
    • 6.8.3.1 Corporate Strategies
    • 6.8.3.2 Business Strategies
  • 6.8.4 Analyst Perspective
• 6.9 Siemens Healthineers AG
  • 6.9.1 Company Overview
  • 6.9.2 Role of Siemens Healthineers AG in the Acute Care Syndromic Testing Market
  • 6.9.3 Financials
  • 6.9.4 Analyst Perspective

관련자료